WuXi XDC

What WuXi XDC does

WuXi XDC (2268.HK) is a contract research, development, and manufacturing organization (CRDMO) focused exclusively on antibody-drug conjugates (ADCs) and other bioconjugates, including antibody-oligonucleotide conjugates and dual-payload constructs. Founded in 2013 as a joint venture between WuXi Biologics and WuXi STA, the company offers an integrated discovery-to-commercial platform covering antibody intermediate production, payload and linker synthesis, bioconjugation, analytical characterization, and GMP manufacturing. Proprietary platforms include WuXiDARx and WuXiDAR4 for conjugation chemistry, X-LinC for linker design, and WuXiTecan-2 for payload chemistry, with a disclosed DNA-to-IND timeline of 15 months versus an industry norm of 24+ months. As of 2025, the company reports 252 integrated CMC projects (70 newly signed in the year), 900+ historical ADC/XDC projects, and 19,000+ conjugates delivered for 500+ global clients.

WuXi XDC generates revenue through fee-for-service contracts, milestone payments tied to development and regulatory progress, and commercial manufacturing supply, with a project-based pricing model. Strategic partnerships and platform out-licensing (e.g., WuXiTecan-2 to Earendil Labs) are an emerging revenue line. The customer base spans large pharma (13 of the top 20 global pharmaceutical companies) and emerging biotech, served from facilities in Wuxi, Changzhou, and Shanghai, with a new Singapore site operational by end of 2025 to serve Western clients and reduce geopolitical concentration. The 2025 acquisition of BioDlink for $400M extends capability upstream into standalone biologics manufacturing, deepening the one-stop-shop positioning.

In 2025, the company reported revenue of RMB 5,944 million (approximately US$830M), up 46.7% year-over-year, with gross profit of RMB 2,139 million (up 72.5%) and adjusted net profit of RMB 1,559 million (up 69.9%). The total backlog stood at US$1.49 billion, up 50.3%, providing strong visibility into 2026–2027 growth. Operations are supported by 2,000+ global employees and the company holds ISO 22301 certification and a Morningstar Sustainalytics ESG Low Risk rating. In 2025, WuXi XDC received the World ADC Awards for Best CDMO and Best CRO.

Name

WuXi XDC

Legal name

WuXi XDC Cayman Inc.

Website

https://wuxixdc.com

Company type

Public

Founded year

2013

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

WuXi XDC (2268.HK) is a global CRDMO focused exclusively on antibody-drug conjugates and bioconjugates, offering integrated discovery, development, and GMP manufacturing to 500+ pharma and biotech clients from facilities in China and Singapore.

Ownership category

akta.pro rank

Product category

Biologics Contract Development and Manufacturing (CRDMO)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Services-Testing Laboratories (8734)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Analytical Development & QC Testing (Release/Stability/Potency) (HLAGAGAF)

Keywords

• Antibody drug conjugates
• Bioconjugate development
• Bioconjugate manufacturing
• Contract research development
• Payload linker services

Headquarters

HQ city

Wuxi

HQ country

China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Contract Research, Development, and Manufacturing Services: WuXi XDC generates revenue through comprehensive CRDMO services for ADCs and bioconjugates, including discovery, process development, analytical development, GMP manufacturing of drug substance and drug product. Revenue model is project-based with milestone payments across development stages from early discovery through commercial manufacturing.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

WuXi XDC is a pure-play CRDMO (Contract Research, Development and Manufacturing Organization) providing single-source, end-to-end services for antibody drug conjugates (ADCs) and other bioconjugates. Its integrated platform spans bioconjugation discovery, process and analytical development, formulation, and GMP manufacturing of both drug substance and drug product—including mAb intermediates, payload-linker chemistry, conjugation, fill-finish and lyophilization—all consolidated in one site to compress DNA-to-IND timelines.

Product overview

WuXi XDC is a leading global CRDMO (Contract Research, Development and Manufacturing Organization) providing end-to-end services for antibody drug conjugates (ADCs) and other bioconjugates (XDCs). The company offers a comprehensive integrated platform spanning bioconjugation discovery, process development, analytical development, formulation, and GMP manufacturing for both drug substances and drug products. Key services include mAb intermediate production, payload-linker R&D and manufacturing, conjugation, and fill-finish operations. The company's proprietary technology platforms include WuXiDARx™ (site-specific conjugation), WuXiDAR4™ (interchain conjugation), X-LinC (stable linker), and WuXiTecan-2™ (hydrophilic exatecan payload-linker). WuXi XDC operates manufacturing facilities in Wuxi, Changzhou, Shanghai (China), and Singapore, offering both integrated discovery services and commercial-scale manufacturing capabilities.

Differentiator

Problem solved

Functional benefit

Brands

• XDC ConjuTech: Brand name used for WuXi XDC's bioconjugation research, development, and manufacturing services

Products and services

• Bioconjugation Discovery Services Integrated R&D discovery services generating, engineering, evaluating and optimizing ADC/bioconjugate lead candidates to maximize drug discovery efficiency for pharmaceutical and biotech clients.
• Bioconjugation Process Development Process development, scale-up, and tech-transfer to GMP manufacturing services for ADCs, other drug bioconjugates, and diagnostic/imaging reagents at CMC stage.
• Analytical Development Analytical, bioassay and biosafety laboratory services supporting development functions and characterizing intermediates and bioconjugates throughout preclinical and clinical development stages.
• Formulation and DP Development Formulation and drug product development team designing liquid, frozen or lyophilized dosage forms for bioconjugates, including special dosage forms for products containing nanoparticles and advanced molecular complexes.
• GMP mAb Intermediate and Conjugation Manufacturing Conjugation manufacturing services from development batches to clinical and commercial supply, including production of antibodies and payload-linkers and QC laboratory services.
• GMP Formulation, Fill and Lyophilization Fully automated, isolator-based aseptic systems filling liquid and lyophilized products in 2R/6R/10R/20R/50R vial sizes, providing GMP filling services for ADCs, other bioconjugates, cytotoxic compounds and small molecule products.
• Payload and Linker R&D and Manufacturing Comprehensive and integrated discovery, CMC development, and cGMP manufacturing of chemical intermediates used in ADC and bioconjugate production, including ready-to-conjugate off-the-shelf payload-linkers.
• Ready-Made Payloads & Linkers Library Growing library of GMP and non-GMP grade ready-to-conjugate chemical payloads, linkers and payload-linkers for ADC and bioconjugate production, including MMAE, MMAF, Exatecan, DM1, DM4, SN38, PBD, Eribulin, PBD Dimers and Calicheamicin.
• WuXiDARx™ Conjugation Platform Proprietary site-specific conjugation platform based on inter-chain cysteines that eliminates the need for antibody engineering, enzymes, or column purification, enabling precise DAR control for ADC development.
• WuXiDAR4™ Technology Platform Innovative interchain conjugation technology that enhances the therapeutic window of ADCs while maintaining highly efficient manufacturing processes; seven ADCs leveraging this technology have entered clinical development globally.
• X-LinC Linker Technology Novel linker technology demonstrating superior stability compared with traditional maleimide linkers, translating to improved safety profiles and enhanced in vivo performance.
• WuXiTecan-2™ Payload-Linker Platform Proprietary hydrophilic exatecan payload-linker with enhanced hydrophilicity and superior plasma stability, suitable for both single and dual-payload ADC development; demonstrated favorable PK profiles in rodent and cynomolgus monkey studies.

Quantifiable outcome

• DNA-to-IND timeline reduced to 15 months or less, nearly half the industry average
• +5 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Seven partnerships are on record, tiered core, major and minor.

• BioDlinkcoreStrategic or Co-development Partner · 4 June 2026BioDlink became a controlled subsidiary of WuXi XDC following Suzhou site acquisition. Joint 2026 Open Day event marked first major customer-facing activity since acquisition. Combined integrated ADC/XDC CRDMO platform aims to accelerate development and commercialization of next-generation bioconjugate therapies.
• Akari TherapeuticscoreStrategic or Co-development Partner · 10 April 2026Strategic partnership supporting Akari's ADC pipeline advancement, expected to accelerate AKTX-101 toward first-in-human clinical trials by late 2026/early 2027. Collaboration extends beyond traditional CDMO engagement covering development, manufacturing, and regulatory activities. AKTX-101 uses a novel PH1 payload targeting RNA splicing in cancer cells for metastatic urothelial cancer.
• Earendil LabsmajorTechnology or Integration · 27 February 2026WuXi XDC granted Earendil Labs an exclusive global license to its WuXiTecan-2 payload-linker technology platform for developing next-generation ADCs. Total potential deal value could reach approximately $885 million comprising upfront, development, regulatory, and sales milestone payments, plus tiered royalties on net sales. WuXi XDC supports CMC development and manufacturing while Earendil Labs focuses on product development, global regulatory submissions, and commercialization.
• Mabsoft TherapeuticsminorStrategic or Co-development Partner · 3 April 2025Strategic partnership to accelerate development of next-generation Immune-Stimulating Antibody Conjugates (ISACs). Collaboration combines Mabsoft's ISAC technology with WuXi XDC's integrated development platform.
• AbTismajorTechnology or Integration · 11 March 2025MOU partnership bringing together AbTis' proprietary site-selective conjugation platform AbClick® and WuXi XDC's integrated discovery services and all-in-one development & manufacturing platform. WuXi XDC incorporates AbTis' advanced site-selective conjugation technologies and facilitates potential collaborations between AbTis and its extensive client network.
• LigaChem BiosciencescoreStrategic or Co-development Partner · 25 February 2025Expanded MOU strengthening partnership to accelerate development of next-generation ADC therapies. WuXi XDC's fully integrated ADC discovery service platform boosts speed and efficiency of LigaChem's ADC development programs. LigaChem utilizes WuXi XDC's integrated development and manufacturing platform for multiple ADC projects. Initial collaboration began in 2021.
• Pharmadule MorimatsumajorStrategic or Co-development Partner · 14 October 2024Partnership for modular facilities delivery to WuXi XDC's Singapore manufacturing site. Over 200 modules supplied by Pharmadule Morimatsu enable seamless production of drug substances and drug products at clinical and commercial scales. Facility designed with world-class multi-product manufacturing line for ADC/XDC development requirements.

Scale indicators18 records

Recent moves13 records

Expansion highlights5 records

Market position

Competitive moat6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/wuxi-xdc

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about WuXi XDC